Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive ...

Shoreline Biosciences, Inc., a biopharmaceutical company developing disease modifying iNK cell therapies for autoimmune ...

In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem ...

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Fate Therapeutics (FATE – Research Report), with a price target ...

Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant ...

Based on these selected genes, they developed a machine learning-based scoring system, "hiPSCore," which was trained on 15 iPSC lines and validated on an additional 10 iPSC lines. The hiPSCore ...

Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and its major active metabolite significantly and ...

Two years after surgery, three patients experienced improved corneal transparency with no serious side effects.

d iT, and aß iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to ...